A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)

The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.

Start Date21 Mar 2018

Sponsor / Collaborator

Incyte Corp.

NCT03341936 / Active, not recruitingPhase 2IIT

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck

This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck.
The immunotherapy drugs involved in this study are:
Nivolumab (Opdivo™)
Lirilumab

Start Date15 Mar 2018

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

NCT03203876 / CompletedPhase 1

A Phase 1 Study of the Safety and Pharmacokinetics of Anti-KIR Monoclonal Antibody (Lirilumab, BMS-986015) in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) or in Combination With Nivolumab and Anti-CTLA-4 Monoclonal Antibody (Ipilimumab, BMS-734016) in Advanced and/or Metastatic Solid Tumors

The purpose of this study is to determine whether lirilumab in combination with nivolumab or in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or metastatic solid tumors

Start Date14 Jul 2017

Sponsor / Collaborator

Bristol Myers Squibb Co.

[+1]

100 Clinical Results associated with KIR2DL3

100 Translational Medicine associated with KIR2DL3

0 Patents (Medical) associated with KIR2DL3

279

Literatures (Medical) associated with KIR2DL3

27 Aug 2024·Clinical Chemistry and Laboratory Medicine (CCLM)

The role of Killer immunoglobulin-like receptors (KIRs) in the genetic susceptibility to non-celiac wheat sensitivity (NCWS)

Article

Author: Agnello, Luisa ; Vidali, Matteo ; Giuliano, Alessandra ; Tamburello, Martina ; Candore, Giuseppina ; Carroccio, Antonio ; Lo Sasso, Bruna ; Ciaccio, Marcello ; Masucci, Anna ; Vassallo, Roberta ; Gambino, Caterina Maria ; Scazzone, Concetta ; Ciaccio, Anna Maria ; Mansueto, Pasquale ; Massa, Davide ; Seidita, Aurelio

AbstractObjectivesNon-celiac wheat sensitivity (NCWS) is an emerging clinical condition characterized by gastrointestinal and extraintestinal symptoms following the ingestion of gluten-containing foods in patients without celiac disease (CD) or wheat allergy. Despite the great interest for NCWS, the genetic risk factors still need to be fully clarified. In this study, we first assessed the possible contribution of KIR genes and KIR haplotypes on the genetic predisposition to NCWS.MethodsFifty patients with NCWS, 50 patients with CD, and 50 healthy controls (HC) were included in this study. KIR genes and KIR genotyping were investigated in all subjects by polymerase chain reaction with the sequence oligonucleotide probe (PCR-SSOP) method using Luminex technology.ResultsWe found a statistically different distribution of some KIR genes among NCWS, CD, and HC. Specifically, NCWS showed a decreased frequency of KIR2DL1, −2DL3, −2DL5, −2DS2, −2DS3, −2DS4, −2DS5, and −3DS1 genes, and an increased frequency of -3DL1 gene respect to both CD and HC. No difference was detected in the KIR haplotype expression. At the multivariate analysis, KIR2DL5, −2DS4, and −2DS5 were independent predictors of NCWS.ConclusionsOur findings suggest a role of KIR genes in NCWS susceptibility, with KIR2DL5, −2DS4, and −2DS5 having a protective effect. Further large-scale multicentric studies are required to validate these preliminary findings.

01 Aug 2024·HLA

Killer‐cell immunoglobulin‐like receptor polymorphism is associated with COVID‐19 outcome: Results of a pilot observational study

Article

Author: Bartol‐Sánchez, M. R. ; Alcoceba, M. ; Presa, D. ; Gil‐Etayo, F. J. ; López‐Sánchez, E. ; Sánchez, P. L. ; Chillón, M. C. ; González, M. ; Muñoz, J. L. ; García‐Sanz, R. ; Gutiérrez‐Zufiaurre, M. N. ; Niño‐Ramírez, J. E. ; Boix, F. ; González‐Calle, D. ; García‐Álvarez, M. ; López‐Bernús, A. ; Compán‐Fernández, O. ; Terradillos‐Sánchez, P. ; Eiros, R. ; Marcos, M.

The pathogenesis of COVID‐19 warrants unravelling. Genetic polymorphism analysis may help answer the variability in disease outcome. To determine the role of KIR and HLA polymorphisms in susceptibility, progression, and severity of SARS‐CoV‐2 infection, 458 patients and 667 controls enrolled in this retrospective observational study from April to December 2020. Mild/moderate and severe/death study groups were established. HLA‐A, ‐B, ‐C, and KIR genotyping were performed using the Lifecodes® HLA‐SSO and KIR‐SSO kits on the Luminex® 200™ xMAP fluoroanalyser. A probability score using multivariate binary logistic regression analysis was calculated to estimate the likelihood of severe COVID‐19. ROC analysis was used to calculate the best cut‐off point for predicting a worse clinical outcome with high sensitivity and specificity. A p ≤ 0.05 was considered statistically significant. KIR AA genotype protected positively against severity/death from COVID‐19. Furthermore, KIR3DL1, KIR2DL3 and KIR2DS4 genes protected patients from severe forms of COVID‐19. KIR Bx genotype, as well as KIR2DL2, KIR2DS2, KIR2DS3 and KIR3DS1 were identified as biomarkers of severe COVID‐19. Our logistic regression model, which included clinical and KIR/HLA variables, categorised our cohort of patients as high/low risk for severe COVID‐19 disease with high sensitivity and specificity (Se = 94.29%, 95% CI [80.84–99.30]; Sp = 84.55%, 95% CI [79.26–88.94]; OR = 47.58, 95%CI [11.73–193.12], p < 0.0001). These results illustrate an association between KIR/HLA ligand polymorphism and different COVID‐19 outcomes and remarks the possibility of use them as a surrogate biomarkers to detect severe patients in possible future infectious outbreaks.

01 Jul 2024·Heliyon

Association between Killer Immunoglobulin-like receptor genes and susceptibility to inflammatory bowel disease: An updated meta-analysis

Article

Author: García-Torreros, César ; Graciano-Machuca, Omar ; Recendiz-Nuñez, Miguel Ángel ; Huerta-Olvera, Selene Guadalupe ; Enciso-Vargas, Moisés ; Sifuentes-Franco, Sonia ; Ponce, Giovanna Isabel ; Rodríguez-Sánchez, Irám Pablo

BackgroundSeveral studies have associated members of the KIR genes as susceptibility factors to inflammatory bowel diseases (IBD): ulcerative colitis (UC) and Crohn's disease (CD).ObjectivesTo assess the association between the presence and absence KIR genes and IBD susceptibility through a meta-analysis.MethodA systematic search was performed through the PubMed, Scopus, and Web of Science databases to obtain relevant articles published before March 2024. Associations between genes and susceptibility to IBDs were estimated by OR with 95 % CI.ResultsWe found positive associations of the KIR2DS1 and KIR2DS3 genes with susceptibility to UC, while the KIR2DL3 and KIR2DS4 ^full genes showed a negative association. In addition, the KIR2DS1, KIR2DS3, KIR2DS4, KIR2DS5, and KIR3DS1 genes showed a positive association with susceptibility to CD, whereas the KIR2DL1 gene showed a negative association.ConclusionsOur meta-analysis indicates that individuals carrying the KIR2DS1 and KIR2DS3 genes exhibit increased susceptibility to UC, whereas carriers of the KIR2DS1, KIR2DS3, KIR2DS4, KIR2DS5, and KIR3DS1 genes are more prone to CD. However, further studies are required to clarify the role of the KIR genes and their corresponding ligands in the pathology of IBD.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

KIR2DL3

Basic Info

Related

Analysis